DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

168.75 1.28 (0.76%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $168.75 0.76%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $166.89
Previous Close $167.47
Daily Range $165.00 - $172.11
52-Week Range $82.51 - $172.11
Market Cap $12.7B
P/E Ratio 149.53
Dividend (Yield) $0.00 (0.0%)
Volume 973,130
Average Daily Volume 1,019,813
Current FY EPS $1.06

Sector

Healthcare

Industry

Drugs

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary

5 Things Johnson & Johnson's Management Wants You to Know

Since earnings reports only scratch the surface of how a company is performing, we decided to take a deeper dive into what Johnson & Johnson's management had to say about its latest quarter. Here are the five most important things you need to know as an investor.

Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog

3 Biotechs Looking Good this Earnings Season - Earnings ESP

Stocks That Battle Cancer Were The Best-Performing Biotechs In January

New Lifetime High Reached By Pharmacyclics (PCYC)

Why You Shouldn't Bet Against Pharmacyclics (PCYC) Stock - Tale of the Tape

Pharmacyclics Has Moderate Upside And A Very Limited Downside

Why Pharmacyclics (PCYC) Could Be Positioned for a Surge? - Tale of the Tape

Can The Uptrend Continue for Pharmacyclics (PCYC)? - Tale of the Tape

Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst

Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $168.75 (0.76%)
Current stock: PCYC
AMGN $152.26 (-2.63%)
Current stock: AMGN
GILD $104.83 (0.62%)
Current stock: GILD
BIIB $389.16 (10.17%)
Current stock: BIIB